Wedbush Has Bullish Outlook for Zenas BioPharma Q3 Earnings

Key Points

• Wedbush upgraded their Q3 2025 earnings estimate for Zenas BioPharma to $1.91 per share, significantly up from a previous expectation of ($1.33).
• The stock holds a current consensus rating of "Buy" from analysts, with a target price averaging at $36.67.
• Zenas BioPharma's recent earnings report revealed a loss of ($1.25) per share, missing analysts' consensus estimate of ($1.02) by ($0.23).

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) - Stock analysts at Wedbush lifted their Q3 2025 EPS estimates for Zenas BioPharma in a note issued to investors on Tuesday, September 2nd. Wedbush analyst M. Fan now forecasts that the company will earn $1.91 per share for the quarter, up from their prior estimate of ($1.33). Wedbush has a "Outperform" rating and a $35.00 price objective on the stock. Wedbush also issued estimates for Zenas BioPharma's Q4 2025 earnings at $1.49 EPS, FY2025 earnings at $1.37 EPS, Q1 2026 earnings at ($1.36) EPS, Q2 2026 earnings at ($1.37) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.40) EPS, FY2026 earnings at ($5.51) EPS, FY2027 earnings at ($1.80) EPS, FY2028 earnings at ($4.57) EPS and FY2029 earnings at ($2.73) EPS.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.23).

A number of other research firms also recently issued reports on ZBIO. Wall Street Zen upgraded Zenas BioPharma from a "sell" rating to a "hold" rating in a research note on Friday, September 5th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Zenas BioPharma in a research note on Friday, May 16th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $36.67.

Zenas BioPharma Stock Down 4.7%

Shares of Zenas BioPharma stock traded down $1.03 during trading hours on Friday, reaching $20.81. 99,650 shares of the stock traded hands, compared to its average volume of 185,961. The business's 50 day moving average is $15.22. The company has a market capitalization of $876.31 million and a price-to-earnings ratio of -5.86. Zenas BioPharma has a one year low of $5.83 and a one year high of $26.25.

Institutional Trading of Zenas BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. New York State Common Retirement Fund bought a new position in Zenas BioPharma during the first quarter valued at $49,000. Nuveen LLC bought a new stake in Zenas BioPharma during the 1st quarter valued at $250,000. Jefferies Financial Group Inc. bought a new stake in Zenas BioPharma during the 1st quarter valued at $348,000. Geode Capital Management LLC raised its position in shares of Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock worth $3,621,000 after acquiring an additional 16,461 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Zenas BioPharma by 71.3% in the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company's stock worth $191,000 after acquiring an additional 8,207 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.